Dr. Anna Karen Archbold, MD

Dr. Archbold practices at John Sealy Hospital in Galveston, Texas, part of The University of Texas System.

Dr. Archbold's NPI, 1265053169, was assigned on May 1, 2020. Dr. Archbold graduated from University of Texas Rio Grande Valley School of Medicine in 2020. Dr. Archbold's Texas license number on file is BP10071288.

Dr. Archbold's primary practice is John Sealy Hospital, at 301 University Boulevard, Galveston, TX 77555 in Galveston County. The practice phone is (409) 772-1011.

Dr. Archbold's primary practice is John Sealy Hospital in Galveston, Texas, part of The University of Texas System. The medical group on file is UTMB Faculty Group Practice.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Archbold practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Archbold's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Archbold is board certified in internal medicine by the American Board of Internal Medicine. Dr. Archbold has a license on file in Texas.

Dmand AI lists chronic diabetes and muscle pain, fibromyalgia, and limb pain among the conditions Dr. Archbold treats.

CMS data shows 84 Medicare services from Dr. Archbold across 2 procedure codes in 2024, for 54 Medicare patients. Medicare paid $6,054 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 54 Medicare patients who saw Dr. Archbold in 2024. The largest group is 65 to 74, with 26 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 30% are also on Medicaid. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Archbold's median patient age at 69, with 63% women.

In 2024, Dr. Archbold wrote 404 Medicare Part D claims for 66 patients. 77% of them were for generic drugs. CMS names the drug for 116 of them, across 6 drugs with 11 or more claims each, at $1,263 in total drug cost. In 2023, CMS named 193 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Archbold for performance year 2024, reported as part of a group.

Dmand AI links 3 papers to Dr. Archbold in 2019. 2019 was the busiest year, with 2. Dr. Archbold's most frequent co-author is John Joseph Digiovanni, DO.

CMS Open Payments shows 1 general payment to Dr. Archbold from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Sanofi and Genzyme US Companies paid the most, $124.

Dr. Archbold graduated from University of Texas Rio Grande Valley School of Medicine in 2020.

Dr. Archbold is in network with 5 carriers, including Blue Cross Blue Shield of Michigan, HCSC and Blue Cross Blue Shield of Massachusetts. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.